Австралия - английский - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sildenafil citrate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate -

Сингапур - английский - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 129.082mg eqv bosentan - tablet, film coated - 125 mg - bosentan monohydrate 129.082mg eqv bosentan 125 mg

Сингапур - английский - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 64.541mg eqv bosentan - tablet, film coated - 62.5 mg - bosentan monohydrate 64.541mg eqv bosentan 62.5 mg

Австралия - английский - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate; hypromellose; croscarmellose sodium; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; calcium hydrogen phosphate; croscarmellose sodium; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Соединенные Штаты - английский - NLM (National Library of Medicine)

par pharmaceutical, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to -pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1) ]. in patients with pah requiring transition from epoprostenol, treprostinil is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental effects were seen